Prevention and Treatment of Spontaneous Mammary Carcinoma With Dendritic Tumor Fusion Cell Vaccine
Abstract
We have developed a vaccine based on the fusions of DC with tumor cells The fusion cells express MHC class I and II, costimulatory molecules and tumor-derived peptides. Immunization with dendritic/tumor fusion cells (FC/MUC1) prevented MC38/MUC1 tumor cell challenge and eradicated established MUC1-positive pulmonary metastasis in MUC1 transgenic mice (MUC1.Tg) In the present study MUC1 transgenic mice are crossed with strains that express polyoma middle T antigen (MTag) driven by the mouse mammary tumor virus (MMTV-LTR) promoter. The new breeder (MMT mice) develops spontaneous mammary carcinoma. We demonstrate that MMT or MT mice form mammary carcinoma with three stages: (1) latent stage from new born to 3 weeks old. (2) premalignant stage from age of 4 weeks to 5 weeks. (3) stage of carcinoma formation from age of 6 weeks or older. Immunization with DC/tumor fusion cells in the premalignant stage rendered the 78% mice tree of disease. These results match our hypothesis that immunization with fusion cells can generate an effective antitumor response to block the progression of premalignant lesion in MMT mice.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2001
- Accession Number
- ADA394250
Entities
People
- Jianlin Gong
Organizations
- Dana–Farber Cancer Institute